NASDAQ · Biotechnology · USD

Kiora Pharmaceuticals, Inc. (KPRX) Stock Analysis

Kiora Pharmaceuticals, Inc. (KPRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KPRX

$2.55

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KPRX with… →

KPRX Key Statistics

As of Sep 4, 2026

Trading

Open: $2.58
Previous Close: $2.55
Day's Range: 2.54–2.63
52-Week Range: 1.77–2.95
Volume: 4.50K
Beta: −0.33

Valuation

Market Cap: $11.28M
P/E Ratio: unprofitable
EPS (ttm): −2.41

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$10.84M−401.42%
Profit margin: 0.00%
Shares Outstanding: 4.42M
1-Year Return: −6.59%

Dividend and dates

Avg Volume: 20.61K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KPRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+43.66%−94.32%+29.44%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+29.44%
2025	−40.30%
2024	−29.76%
2023	−84.78%
2022	−94.32%
2021	−69.37%
2020	−50.80%
2019	+43.66%
2018	−56.54%
2017	−34.36%
2016 (partial year)	−23.11%

As of September 4, 2026.

KPRX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$10.84M	—
2024	$16.00M	$3.59M	22.5%
2023	$0.00	−$12.51M	—
2022	$0.00	−$13.58M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$9.46M	−$10.84M	—
2024	$16.00M	—	$5.58M	$3.59M	22.5%
2023	$0.00	—	−$8.69M	−$12.51M	—
2022	$0.00	—	−$11.73M	−$13.58M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KPRX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	KPRX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Kiora Pharmaceuticals, Inc. (KPRX) at $11.28M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 13 employees.

The 52-week range on file runs from $1.77 to $2.95. KPRX last closed at $2.55 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 44.48% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Against the prior fiscal year total of $16.00M, that is a change of −100.00%. The same year closed with a net loss of $10.84M. Profit margin runs at 0%. Trailing earnings per share are −2.41.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −6.59%. Measured over 10 years, that is −56.06% a year compounded. The reported beta is −0.33. Annualized volatility over the trailing 10 years is 114.01%.

Growth & Income

The record shows no dividend for KPRX.

The strongest complete calendar year on file is 2019 at +43.66%; the weakest is 2022 at −94.32%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the price is +29.44%.

Peer Comparison

Kiora Pharmaceuticals, Inc. (KPRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Kiora Pharmaceuticals, Inc.	KPRX	$11.28M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Kiora Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Visit website →